CML treatment options are diverse, and informed choices are crucial for patients. Life expectancy for newly diagnosed patients is improving, especially in India, where patients are generally younger and more symptomatic. The ELTS score may better stratify risk for Indian patients compared to the SoCal scoring system. Key goals include achieving treatment-free remission and minimizing toxicities, with specific recommendations for using Imatinib and considering patient comorbidities.